Publication of Phase III Results in The Lancet

Summary by AI BETAClose X

HUTCHMED announced the publication of Phase III SACHI trial results in The Lancet, demonstrating that the combination of savolitinib and osimertinib significantly improved progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) and MET amplification after prior EGFR-TKI treatment. The trial, which randomized 211 patients, showed a median PFS of 8.2 months for the savolitinib and osimertinib combination versus 4.5 months for chemotherapy, with a hazard ratio of 0.34. The objective response rate was 58% for the combination compared to 34% for chemotherapy. This combination received regulatory approval in China in June 2025.

Disclaimer*

UK 100

Latest directors dealings